|
| 37699031 | Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management. | Neuro Oncol | 2024 |
| 36288512 | Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations. | J Clin Oncol | 2023 |
| 37585632 | Headway against Brain Tumors with Molecular Targeting of IDH-Mutant Gliomas. | N Engl J Med | 2023 |
| 37188158 | Hepatotoxicity from high-dose methotrexate in primary central nervous system lymphoma. | Neurooncol Pract | 2023 |
| 37100086 | Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review. | Neuro Oncol | 2023 |
| 37470973 | Disease Assessments in Patients with Glioblastoma. | Curr Oncol Rep | 2023 |
| 37262389 | Fatal Intracranial Hemorrhage With Belzutifan in von Hippel-Lindau Disease-Associated Hemangioblastoma: A Case Report. | JCO Precis Oncol | 2023 |
| 36239925 | Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. | Neuro Oncol | 2023 |
| 35953567 | MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma. | Neuroradiology | 2023 |
| 34724065 | EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults. | Neuro Oncol | 2022 |
| 35857249 | The landscape of brain tumor mimics in neuro-oncology practice. | J Neurooncol | 2022 |
| 35788556 | Vascular complications in patients with brain tumors. | Curr Opin Oncol | 2022 |
| 35664553 | Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). | Neurooncol Adv | 2022 |
| 35561283 | Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. | J Clin Oncol | 2022 |
| 36659964 | Navigating disability insurance in the American healthcare system for the low-grade glioma patient. | Neurooncol Pract | 2022 |
| 35908833 | EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. | Neuro Oncol | 2022 |
| 35938683 | Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors. | Biomed Chromatogr | 2022 |
| 36225651 | A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. | Neurooncol Adv | 2022 |
| 35913658 | Current Considerations in the Treatment of Grade 3 Gliomas. | Curr Treat Options Oncol | 2022 |
| 34932393 | Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. | J Clin Oncol | 2022 |
| 34898238 | Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. | J Clin Oncol | 2022 |
| 35137214 | Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas. | Neuro Oncol | 2022 |
| 34383073 | Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk? | Neuro Oncol | 2022 |
| 34607715 | Central Nervous System Complications Among Oncology Patients. | Hematol Oncol Clin North Am | 2022 |
| 32678879 | CODEL: phase III study of RT, RTâ¿¿+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. | Neuro Oncol | 2021 |
| 33720339 | Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. | Blood Adv | 2021 |
| 33622704 | Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. | Clin Cancer Res | 2021 |
| 33614346 | Encephalomyeloradiculoneuropathy Revealing a Rare Case of Intravascular Large B-Cell Lymphoma. | Cureus | 2021 |
| 33661425 | Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma. | J Neurooncol | 2021 |
| 34515791 | The blood-brain barrier limits the therapeutic efficacy of antibody-drug conjugates in glioblastoma. | Neuro Oncol | 2021 |
| 34174071 | SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. | Neuro Oncol | 2021 |
| 34007966 | The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. | Neurooncol Adv | 2021 |
| 34260012 | Correction to: Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma. | J Neurooncol | 2021 |
| 34194618 | A new class of radiosensitizers for glioblastoma. | Oncotarget | 2021 |
| 34164780 | Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma. | J Neurooncol | 2021 |
| 33361259 | Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype. | Neurology | 2021 |
| 32836908 | Out of the laboratory and into the classroom: the future of artificial intelligence in education. | AI Soc | 2021 |
| 32327434 | Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes. | AJNR Am J Neuroradiol | 2020 |
| 33664968 | Predictors of early, recurrent, and intractable seizures in low-grade glioma. | Neurooncol Pract | 2020 |
| 31714193 | MRI and CT Identify Isocitrate Dehydrogenase <i>(IDH)</i>-Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization. | Radiology | 2020 |
| 32601979 | Neurological and Medical Complications in Brain Tumor Patients. | Curr Neurol Neurosci Rep | 2020 |
| 32909115 | Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign. | J Neurooncol | 2020 |
| 32666272 | Correction to: Neurological and Medical Complications in Brain Tumor Patients. | Curr Neurol Neurosci Rep | 2020 |
| 32277236 | Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic. | Neuro Oncol | 2020 |
| 32328653 | Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. | Neuro Oncol | 2020 |
| 32328652 | Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. | Neuro Oncol | 2020 |
| 30422717 | FDG PET/MRI Coregistration Helps Predict Response to Gamma Knife Radiosurgery in Patients With Brain Metastases. | AJR Am J Roentgenol | 2019 |
| 31832212 | Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas. | Neurooncol Pract | 2019 |
| 32914038 | Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. | JCO Precis Oncol | 2019 |
| 29899381 | Correction to: Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma. | Cell Death Differ | 2019 |